Conditions
Human Immunodeficiency Virus Type 1 Infection
Trial Purpose
The investigators are trying to find better treatments for people with HIV-1. In this clinical study, the investigators wish to see how well a new treatment called ISL+ULO, taken once per week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. The investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also wish to understand whether the new treatment, MK-8591B, is safe and how well people can tolerate it.
NATIONAL TRIAL REFERENCE NUMBER
NCT06891066
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About The Trial
Trial Phase
Trial Phase 2
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Trial start and end dates
- Actual study start date 14 April 2025
- Estimated primary completion date 24 September 2027
- Estimated study completion date 24 September 2027
Trial locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about